Atlas Trials

A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma

Clinical trial NCT03033303 · COMPLETED

Trial details

NCT number
NCT03033303
Sponsor
Memorial Sloan Kettering Cancer Center
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Neuroblastoma
Start date
2017-01-23
Primary completion
2025-09-29
Enrollment
59

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.